Options
Histone Deacetylase: Therapeutic Targets in Retinal Degeneration
Author(s)
Date Issued
2015-10-02
Date Available
2020-09-22T14:45:27Z
Abstract
Previous studies report that retinitis pigmentosa (RP) patients treated with the histone deacetylase inhibitor (HDACi) valproic acid (VPA) present with improved visual fields and delayed vision loss. However, other studies report poor efficacy and safety of HDACi in other cohorts of retinal degeneration patients. Furthermore, the molecular mechanisms by which HDACi can improve visual function is unknown, albeit HDACi can attenuate pro-apoptotic stimuli and induce expression of neuroprotective factors. Thus, further analysis of HDACi is warranted in pre-clinical models of retinal degeneration including zebrafish. Analysis of HDAC expression in developing zebrafish reveals diverse temporal expression patterns during development and maturation of visual function.
Sponsorship
Health Research Board
Type of Material
Book Chapter
Publisher
Springer
Series
Advances in Experimental Medicine and Biology
854
Copyright (Published Version)
2016 Springer
Language
English
Status of Item
Peer reviewed
Journal
Bowes Rickman, C., LaVail, M. M., Anderson, R. E., Grimm, C. (eds.). Retinal Degenerative Diseases: Mechanisms and Experimental Therapy
Conference Details
The 16th International Symposium on Retinal Degeneration (RD2014), Pacific Grove, California, United States of America, 13-18 July 2014
ISBN
978-3-319-17120-3
ISSN
0065-2598
This item is made available under a Creative Commons License
File(s)
No Thumbnail Available
Name
XX.Kennedy.docx
Size
35.24 KB
Format
Microsoft Word
Checksum (MD5)
aedc3265a61de602ccfb98f2448a1ec3
Owning collection
Mapped collections